These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30386824)

  • 21. Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.
    Rosenberg AJ; Agrawal N; Pearson A; Gooi Z; Blair E; Cursio J; Juloori A; Ginat D; Howard A; Chin J; Kochanny S; Foster C; Cipriani N; Lingen M; Izumchenko E; Seiwert TY; Haraf D; Vokes EE
    Oral Oncol; 2021 Nov; 122():105566. PubMed ID: 34662771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective registry study of stereotactic magnetic resonance guided radiotherapy (MRgRT) for primary liver tumors.
    Bordeau K; Michalet M; Dorion V; Keskes A; Valdenaire S; Debuire P; Cantaloube M; Cabaillé M; Draghici R; Ychou M; Assenat E; Jarlier M; Gourgou S; Guiu B; Ursic-Bedoya J; Aillères N; Fenoglietto P; Azria D; Riou O
    Radiother Oncol; 2023 Dec; 189():109912. PubMed ID: 37739315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Sinai Robotic Surgery Trial in HPV-related oropharyngeal squamous cell carcinoma (SIRS 2.0 trial) - study protocol for a phase II non-randomized non-inferiority trial.
    Chai RL; Ferrandino RM; Barron C; Donboli K; Roof SA; Khan MN; Teng MS; Posner MR; Bakst RL; Genden EM
    Front Oncol; 2022; 12():965578. PubMed ID: 36091121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of MR-guided radiotherapy accumulated doses for central lung tumors with non-adaptive and online adaptive proton therapy.
    Rabe M; Palacios MA; van Sörnsen de Koste JR; Eze C; Hillbrand M; Belka C; Landry G; Senan S; Kurz C
    Med Phys; 2023 May; 50(5):2625-2636. PubMed ID: 36810708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial clinical experience with magnetic resonance-guided radiotherapy in pediatric patients: Lessons learned from a single institution with proton therapy.
    Hall MD; Mittauer KE; Herrera R; Von Werne K; Kotecha R; Kalman NS; McCulloch J; Alvarez D; McAllister NC; Doty DG; Rzepczynski AE; Deere W; Gutierrez AN; Chuong MD
    Front Oncol; 2022; 12():1037674. PubMed ID: 36713501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial.
    Verweij ME; Tanaka MD; Kensen CM; van der Heide UA; Marijnen CAM; Janssen T; Vijlbrief T; van Grevenstein WMU; Moons LMG; Koopman M; Lacle MM; Braat MNGJA; Chalabi M; Maas M; Huibregtse IL; Snaebjornsson P; Grotenhuis BA; Fijneman R; Consten E; Pronk A; Smits AB; Heikens JT; Eijkelenkamp H; Elias SG; Verkooijen HM; Schoenmakers MMC; Meijer GJ; Intven M; Peters FP
    BMJ Open; 2023 Jun; 13(6):e065010. PubMed ID: 37321815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined Inter- and Intrafractional Plan Adaptation Using Fraction Partitioning in Magnetic Resonance-guided Radiotherapy Delivery.
    Lagerwaard F; Bohoudi O; Tetar S; Admiraal MA; Rosario TS; Bruynzeel A
    Cureus; 2018 Apr; 10(4):e2434. PubMed ID: 29876156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments.
    Chuong MD; Clark MA; Henke LE; Kishan AU; Portelance L; Parikh PJ; Bassetti MF; Nagar H; Rosenberg SA; Mehta MP; Refaat T; Rineer JM; Smith A; Seung S; Zaki BI; Fuss M; Mak RH
    Clin Transl Radiat Oncol; 2023 Jan; 38():161-168. PubMed ID: 36466748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterizing local dose perturbations due to gas cavities in magnetic resonance-guided radiotherapy.
    Shortall J; Vasquez Osorio E; Chuter R; Green A; McWilliam A; Kirkby K; Mackay R; van Herk M
    Med Phys; 2020 Jun; 47(6):2484-2494. PubMed ID: 32144781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial.
    Ristau J; Hörner-Rieber J; Buchele C; Klüter S; Jäkel C; Baumann L; Andratschke N; Garcia Schüler H; Guckenberger M; Li M; Niyazi M; Belka C; Herfarth K; Debus J; Koerber SA
    Radiat Oncol; 2022 Apr; 17(1):75. PubMed ID: 35428327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MR-Guided Radiotherapy for Brain and Spine Tumors.
    Maziero D; Straza MW; Ford JC; Bovi JA; Diwanji T; Stoyanova R; Paulson ES; Mellon EA
    Front Oncol; 2021; 11():626100. PubMed ID: 33763361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment outcomes in oropharynx cancer patients who did not complete planned curative radiotherapy.
    Alfaraj F; Craig T; Huang SH; O'Sullivan B; Su J; Bayley A; Bratman S; Cho J; Giuliani M; Kim J; Ringash J; Waldron J; Hansen A; de Almeida J; Perez-Ordonez B; Weinreb I; Tong L; Xu W; Hope A
    Oral Oncol; 2019 Oct; 97():124-130. PubMed ID: 31521053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The initial experience of MRI-guided precision prone breast irradiation with daily adaptive planning in treating early stage breast cancer patients.
    Ng J; Pennell R; Formenti SC
    Front Oncol; 2022; 12():1048512. PubMed ID: 36505797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of a Paradigm Switch in Diagnosis and Treatment of HPV-Driven Head and Neck Cancer-Striking the Balance Between Toxicity and Cure.
    Tawk B; Debus J; Abdollahi A
    Front Pharmacol; 2021; 12():753387. PubMed ID: 35126105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PATHOS: a phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV) positive oropharyngeal cancer.
    Owadally W; Hurt C; Timmins H; Parsons E; Townsend S; Patterson J; Hutcheson K; Powell N; Beasley M; Palaniappan N; Robinson M; Jones TM; Evans M
    BMC Cancer; 2015 Aug; 15():602. PubMed ID: 26311526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time-Driven Activity-Based Costing of CT-Guided vs MR-Guided Prostate SBRT.
    Parikh NR; Clark MA; Patel P; Kafka-Peterson K; Zaide L; Ma TM; Steinberg ML; Cao M; Raldow AC; Lamb J; Kishan AU
    Appl Radiat Oncol; 2021 Sep; 10(3):33-40. PubMed ID: 34671700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An in-silico assessment of the dosimetric benefits of MR-guided radiotherapy for esophageal cancer patients.
    Boekhoff M; Defize I; Borggreve A; van Hillegersberg R; Kotte A; Lagendijk J; van Lier A; Ruurda J; Takahashi N; Mook S; Meijer G
    Radiother Oncol; 2021 Sep; 162():76-84. PubMed ID: 34237345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Technical Radiotherapy Advances - The Role of Magnetic Resonance Imaging-Guided Radiation in the Delivery of Hypofractionation.
    Gough J; Hall W; Good J; Nash A; Aitken K
    Clin Oncol (R Coll Radiol); 2022 May; 34(5):301-312. PubMed ID: 35305888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Artificial Intelligence in magnetic Resonance guided Radiotherapy: Medical and physical considerations on state of art and future perspectives.
    Cusumano D; Boldrini L; Dhont J; Fiorino C; Green O; Güngör G; Jornet N; Klüter S; Landry G; Mattiucci GC; Placidi L; Reynaert N; Ruggieri R; Tanadini-Lang S; Thorwarth D; Yadav P; Yang Y; Valentini V; Verellen D; Indovina L
    Phys Med; 2021 May; 85():175-191. PubMed ID: 34022660
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.